Indefinite Delivery Contract SPE2DX15D9113

The Defense Logistics Agency (DLA) awarded a single-award indefinite delivery contract (IDC), valued up to $4,999,999, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. This IDC enables DLA to issue firm fixed-price delivery orders for a broad range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military health facilities worldwide.

Under this IDC, DLA has awarded multiple delivery order contracts to DMS Pharmaceutical Group for the supply of specialized pharmaceuticals such as Xolair, Trikafta, Keytruda, Botox, Nucala, Mirena, Nexplanon, and various other prescription drugs and medical supplies. These delivery orders, which do not utilize any set-aside designations, cover a wide range of medical needs including oncology treatments, contraceptives, auto-injectors, and other specialized pharmaceutical products. The contracts are predominantly firm fixed-price and have performance periods through 2024 and 2025, allowing DMS Pharmaceutical Group to serve as a critical supplier in the federal pharmaceutical supply chain.